Advanced Renal Cell Carcinoma

Oncology
7
Pipeline Programs
6
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
5
1
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
250%
Monoclonal Antibody
250%
+ 3 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

H
HutchmedChina - Hong Kong
1 program
1
fruquintinib+sintilimabPhase 2/3Monoclonal Antibody1 trial
Active Trials
NCT05522231Active Not Recruiting265Est. Mar 2025
Amgen
AmgenTHOUSAND OAKS, CA
3 programs
3
AMG 102 at 10 mg/kgPhase 21 trial
AMG 386Phase 21 trial
PanitumumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT00422019Completed61Est. Mar 2009
NCT00467025Completed152Est. Jun 2014
NCT00425035Completed115
Abbott
AbbottABBOTT PARK, IL
1 program
1
ABT-869Phase 21 trial
Active Trials
NCT00486538Completed53Est. Jun 2012
Takeda
TakedaTOKYO, Japan
1 program
1
CabozantinibPhase 2Small Molecule1 trial
Active Trials
NCT03339219Completed35Est. Aug 2020
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
QL1706 Plus LenvatinibPhase 1/2Small Molecule1 trial
Active Trials
NCT05262413UnknownEst. Jul 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Hutchmedfruquintinib+sintilimab
TakedaCabozantinib
AbbottABT-869
AmgenAMG 386
AmgenAMG 102 at 10 mg/kg
AmgenPanitumumab
Qilu PharmaceuticalQL1706 Plus Lenvatinib

Clinical Trials (7)

Total enrollment: 681 patients across 7 trials

NCT05522231Hutchmedfruquintinib+sintilimab

Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

Start: Oct 2022Est. completion: Mar 2025265 patients
Phase 2/3Active Not Recruiting
NCT03339219TakedaCabozantinib

A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma

Start: Dec 2017Est. completion: Aug 202035 patients
Phase 2Completed
NCT00486538AbbottABT-869

Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib

Start: Jun 2007Est. completion: Jun 201253 patients
Phase 2Completed
NCT00467025AmgenAMG 386

AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib

Start: May 2007Est. completion: Jun 2014152 patients
Phase 2Completed
NCT00422019AmgenAMG 102 at 10 mg/kg

A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma

Start: Jan 2007Est. completion: Mar 200961 patients
Phase 2Completed
NCT00425035AmgenPanitumumab

Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2

Start: Feb 2003115 patients
Phase 2Completed
NCT05262413Qilu PharmaceuticalQL1706 Plus Lenvatinib

A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)

Start: Feb 2022Est. completion: Jul 2024
Phase 1/2Unknown

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)